Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

The conference call may be accessed by dialing 877.419.6590 for domestic callers and 719.325.4872 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals Q208 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at http://www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

Upcoming Corporate Presentations

Arena is scheduled to present at the following investment and industry conferences through September 2008:

-- NewsMakers in the Biotech Industry Conference, September 4, 2008, New York, New York

-- UBS Global Life Sciences Conference, September 22-25, 2008, New York, New York

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include s
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
(Date:8/26/2015)... JERUSALEM and BEIJING , August 26, ... Startup Scene with Impressive Acheivements  DiaCardio wins 1 st ...   The competition, led in Israel ... ‎, featured 21 startups from countries including the US, ... and Latin America .  ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial Management ... local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to introduce ... pathways., , Stem Cell Meeting on the Mesa ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently installed ... company has added a AS16 Sharples centrifuge to harvest products after fermentation. The ... fungal fermentation process development. , The new centrifuge greatly expands production capabilities ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New centrifuge and fermentor expand product development capacity at Vets Plus 2
... Host Update Conference Call Today at 8:30 a.m. EST, ... RIGL ) today reported financial results for,the three and ... quarter of 2008, Rigel reported a net loss of $37.7,million, ... $18.9 million, or,$0.61 per share, in the third quarter of ...
... Inc. (Nasdaq: VNUS ), a leading provider of ... disease, today,announced the hiring of Guido Smeets, MD, as ... Dr. Smeets joins VNUS with over 17 years of ... the Head of Clinical Affairs for,Pelikan Technologies, Inc., a ...
... Calif., Oct. 31 SleepQuest has always,followed the essence ... suffer from,undiagnosed and unexplained health problems related to lack ... discuss the,importance of identifying and treating sleep disorders. Sleep ... as a wellness factor.,Studies done by the National Commission ...
Cached Biology Technology:Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 2Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 3Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 4Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 5Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 6VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer 2SleepQuest Tireless in Pursuit of Good Sleep 2
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... Aug. 5, 2015 The biosensors market is ... applications, penetration into newer sectors, and development of devices ... biosensors space has seen the entry of multiple participants ... far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( http://www.frost.com/nee9 ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... Researchers at Wayne State University have discovered a ... undergoing hemodialysis that may prevent cardiovascular disease common in ... at a greater risk for atherosclerosis, a common disease ... can lead to serious problems including heart attack, stroke ...
... KAN. -- People who decrease sitting time and increase ... according to Kansas State University research. Even standing ... at a time -- can improve health and quality ... such as cardiovascular disease, diabetes, heart disease, stroke, breast ...
... initiative bridges the gap between research and the market. ... processes that protect the environment become fully-fledged commercial prospects, ... new product is intended for the aeronautic market, where ... to conventional Cr-based coatings, which provide optimum corrosion protection, ...
Cached Biology News:Wayne State discovers potential treatment for better heart health in hemodialysis patients 2Take a stand and be active to reduce chronic disease, make aging easier, research finds 2The Eco-Innovation initiative rewards ideas for innovative products that protect the environment 2
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the junctophilin-1 ... mouse brain and skeletal muscle homogenates ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
Request Info...
Laminin beta-1/gamma-1 (612C10)...
HSV 1 IgM...
Biology Products: